Additional References

  1. Gopal AK, Kahl BS, de vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370: 1008-1018.
  2. Illidge T, Klein C, Sehn LH, et al. Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treat Rev. 2015;41: 784-792.
  3. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127:2055-63.
  4. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122: 3424-3431.
  5. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations into prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryLancet Oncol. 2015;16: 1111-1122.
  6. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD201 indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS Study. J Clin Oncol. 2015; 33(30):3467-3474.
  7. Van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28: 2853-2858.
  8. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810.





Additional Reading